Remove astrazeneca-guns-wider-ovarian-cancer-market-imfinzi-lynparza-combo-will-fda-buy-plan
article thumbnail

ASCO: AstraZeneca guns for wider ovarian cancer market with Imfinzi-Lynparza combo. Will the FDA buy the plan?

Fierce Pharma

Lynparza may be the most popular PARP inhibitor, but a use restriction in ovarian cancer has been a thorn in AstraZeneca’s side. AstraZeneca is bringing on Imfinzi to potentially help Lynparza reach a broader ovarian cancer population.

FDA 245